title: Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Lehmann
authors.forename: Christiane
authors.initials: C
authors.lastname: Dobbelstein
authors.forename: Martin
authors.initials: M
authors.lastname: Fenner
authors.forename: Daniel
authors.initials: D
authors.lastname: Römermann
authors.forename: Britta
authors.initials: B
authors.lastname: Hasemeier
authors.forename: Kathleen
authors.initials: K
authors.lastname: Metzig
authors.forename: Doris
authors.initials: D
authors.lastname: Steinemann
authors.forename: Guntram
authors.initials: G
authors.lastname: Büsche
authors.forename: Jürgen
authors.initials: J
authors.lastname: Krauter
authors.forename: Arnold
authors.initials: A
authors.lastname: Ganser
authors.forename: Hans
authors.initials: H
authors.lastname: Kreipe
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D050762:Cyclin-Dependent Kinase Inhibitor p15 / Q000235:genetics*; D003582:Cytogenetics / Q000639:trends; D019175:DNA Methylation / Q000187:drug effects* / Q000235:genetics; D000077209:Decitabine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D050762:Cyclin-Dependent Kinase Inhibitor p15; D000077209:Decitabine; D001374:Azacitidine